The OxyContin Story: A Timeline Of Accomplishment And Controversy
With a US FDA advisory committee poised to consider Purdue's postmarket data on OxyContin's abuse deterrent formulation, a Pink Sheet infographic looks back on how the product got here.
You may also be interested in...
Pink Sheet reporter and editors examine the struggle over the FDA’s reputation, whether a coronavirus vaccine could be made available without sponsor cooperation, and the late Supreme Court Justice Ruth Bader Ginsburg’s legacy for pharma.
Governor Cuomo will establish two panels, one examining safety and efficacy and another considering distribution and pricing, to advise the state on how to approach use of coronavirus vaccines once one is approved.
New proposed rule says a manufacturer’s knowledge of the unapproved use of a product does not alone determine intended use. Former FDA lawyer says rule could set off fireworks over the scope of what the agency considers evidence of off-label use.